VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.

导出 OA

翻译打印收藏纠错

第一作者： Steven,Sher

第一单位： Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.

作者： Steven,Sher ^[1] ; Ethan,Whipp ^[1] ; Janek,Walker ^[1] ; Pu,Zhang ^[1] ; Larry,Beaver ^[1] ; Katie,Williams ^[1] ; Shelley,Orwick ^[1] ; Janani,Ravikrishnan ^[1] ; Brandi,Walker ^[1] ; Elizabeth,Perry ^[1] ; Charles,Gregory ^[1] ; Matthew,Purcell ^[1] ; Alexander,Pan ^[1] ; Pearlly,Yan ^[1] ; Lapo,Alinari ^[1] ; Amy J,Johnson ^[2] ; Melanie M,Frigault ^[2] ; Joy M,Greer ^[2] ; Ahmed,Hamdy ^[2] ; Raquel,Izumi ^[2] ; Xiaokui,Mo ^[1] ; Deepa,Sampath ^[3] ; Jennifer,Woyach ^[1] ; James,Blachly ^[1] ; John C,Byrd ^[4] ; Rosa,Lapalombella ^[5]

作者单位： Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA. ^[1] Vincerx Pharma, Palo Alto, CA, USA. ^[2] Department of Hematopoietic Biology & Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[3] Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA. byrd2jc@ucmail.uc.edu. ^[4] Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA. rosa.lapalombella@osumc.edu. ^[5]